Long intergenic non-protein coding RNA 470 (LINC00470)

LINC00470 (Long intergenic non-protein coding RNA 470) is a human long non-coding RNA (lncRNA) gene located on chromosome 18 (C18orf2), characterized by its lack of protein-coding capacity but significant regulatory function at both epigenetic and post-transcriptional levels[1][3][5]. LINC00470 has been shown to promote cell proliferation, invasion, and tumor progression, especially in glioblastoma and other cancers, by acting as a competitive endogenous RNA to sequester tumor-suppressive microRNAs, thereby enhancing oncogene (e.g., MYC) and drug-resistance gene (e.g., ABCC1) expression[2][4][6]. It interacts with key regulatory proteins (FUS, AKT, DNMT3a) to modulate signaling cascades, cellular metabolism, and methylation patterns, and high levels of LINC00470 are correlated with poor prognosis in glioma and astrocytoma patients, establishing its relevance as both a therapeutic target and biomarker[2][4][6]. No direct drug for LINC00470 exists, but its suppression can restore chemosensitivity to agents like temozolomide in glioma models[6].

Other names

C18orf2long intergenic non-protein coding RNA 470LINC00470Putative uncharacterized protein encoded by LINC00470

Functions as a competing endogenous RNA (ceRNA) by sponging microRNAs (e.g., miR-134); Modulates expression of oncogenes (e.g., MYC); Influences methylation status via interaction with MYC and DNMT3a; Regulates activation of AKT pathway via protein-protein and RNA-protein interactions (e.g., with FUS, AKT)